Leiomyomatosis Clinical Trial
Official title:
Lymphangioleiomyomatosis (LAM) Registry
Pulmonary lymphoangioleiomyomatosis (LAM) is a rare destructive lung disease typically
affecting women of childbearing age. Currently, there is no effective therapy for the
disease and the prognosis is poor.
In order to better study this disease, the National Heart, Lung, and Blood Institute (NHLBI)
has developed a registry to keep an official record of patients diagnosed with LAM. This
research project will collect data from 6 health care centers as well as outside physicians.
Researchers hope to provide valuable information about the rate of lung destruction and
quality of life in patients with LAM.
Patients participating in this study will be followed for 5 years. Tissue collected from
these patients may contribute to the development of future studies on the disease processes
of LAM.
Status | Completed |
Enrollment | 400 |
Est. completion date | April 2003 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A and older |
Eligibility |
Informed consent must be obtained from the patient. Patients must be female. Patients must be age 18 or older. Patients with prevalent and incident cases are eligible. Patients with the presence or absence of underlying diagnosis or evidence of Tuberous Sclerosis Complex (TSC) are eligible. Patients must have a diagnosis of LAM confirmed by any of the following criteria: Lung biopsy (transbronchial, surgical, transthoracic) judged to be diagnostic by the Tissue Core pathologists; OR Biopsy of lymph node or other mass judged to be diagnostic by the Tissue Core pathologists; OR High resolution CT scan of the chest which is judged to be diagnostic of LAM with a high degree of certainty by all three of the expert radiologists making up the Imaging Core. Patients may be enrolled in other protocols. |
N/A
Country | Name | City | State |
---|---|---|---|
United States | National Heart, Lung and Blood Institute (NHLBI) | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Heart, Lung, and Blood Institute (NHLBI) |
United States,
Abdulla M, Bui HX, del Rosario AD, Wolf BC, Ross JS. Renal angiomyolipoma. DNA content and immunohistochemical study of classic and multicentric variants. Arch Pathol Lab Med. 1994 Jul;118(7):735-9. — View Citation
Aberle DR, Hansell DM, Brown K, Tashkin DP. Lymphangiomyomatosis: CT, chest radiographic, and functional correlations. Radiology. 1990 Aug;176(2):381-7. — View Citation
Basset F, Soler P, Marsac J, Corrin B. Pulmonary lymphangiomyomatosis: three new cases studied with electron microscopy. Cancer. 1976 Dec;38(6):2357-66. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01707862 -
Surgery for Intravenous Leiomyomatosis
|
N/A | |
Completed |
NCT00628901 -
A Prospective Study Comparing Contour SE™ Microspheres to Embosphere® Microspheres for Treating Symptomatic Uterine Fibroids With Uterine Fibroid Embolization (UFE)
|
Phase 4 | |
Completed |
NCT00361036 -
Comparison Study in the Treatment of Uterine Fibroids Uterine Fibroid Embolization Using BeadBlock™ Embolic Agent
|
Phase 1 |